Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies
/in Chronic Leukemia, International Publications, Malignant Lymphoma /von 2006-04-01 / Leuk. Lymphoma 2006 Apr;47(4):675-82Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses
/in Breast Cancer, International Publications /von 2006-04-01 / Clin. Exp. Immunol. 2006 Apr;144(1):41-7Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses
/in International Publications, Malignant Pleural Mesothelioma /von 2006-03-15 / Eur. Respir. J. 2006 Jun;27(6):1086-95Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation
/in Chronic Leukemia, International Publications /von 2006-03-09 / Leuk. Res. 2006 Jul;30(7):785-94Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin’s lymphoma and multiple myeloma
/in International Publications, Malignant Lymphoma /von 2006-03-07 / Ann. Hematol. 2006 May;85(5):308-14Immunization with heat shock protein 105-pulsed dendritic cells leads to tumor rejection in mice
/in Dendritic Cells, Hyperthermia, International Publications /von 2006-03-03 / Biochem. Biophys. Res. Commun. 2006 Apr;343(1):269-78Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses
/in International Publications, Malignant Melanoma /von 2006-03-01 / Int. J. Oncol. 2006 Mar;28(3):585-93Combined action of virus injection and local tumor irradiation on tumor growth in mice
/in International Publications, Newcastle Disease Virus /von 2006-03-01 / Coll Antropol 2006 Mar;30(1):185-9Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells
/in HIV/AIDS, International Publications /von 2006-02-28 / AIDS 2006 Feb;20(4):627-30
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de